U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06930521) titled 'JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year' on March 31.
Brief Summary: This study focuses on male and female patients being treated for breast cancer that is positive for the HER2 receptor which requires special treatments targeting that receptor. The problem is that these treatments, while effective for the cancer, can sometimes harm the heart. Because of this, patients have to undergo heart tests every three months during treatment, even if they have no history of heart disease or feel fine.
The guidelines for these regular heart tests were established decades ago when these treatments were ...